EPW writ of certiorari
Executive Summary
Supreme Court declines to hear Genetics Institute's EPO petition. The justices offered no comment on the petition denial; however, historically, the Supreme Court has refused to hear patent cases. . . . Rep. Stark on Epogen: During a House Ways & Means Committee hearing on health care reform Oct. 10, the California Democrat decried the high price of the product, noting that Medicare will pay $ 400 mil. for Epogen next year. Stark asked HHS Secretary Sullivan whether the Bush Administration intends "to use Medicare as a form of industrial policy." Sullivan responded that the drug is priced "exceedingly high" but pointed out that EPO is an orphan product for a rare disease. After arranging with Amgen for development, HHS wanted to avoid "changing goalposts once the game was begun," Sullivan said. . . .
You may also be interested in...
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Shire Hopes To Sow Future Deals With $50M Venture Fund
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth